**TGF-β₁ immunohistochemistry and promoter methylation in chronic renal failure rats treated with uremic clearance granules**

Xu-Hong Miao¹,², Chun-Guo Wang¹, Bao-Quan Hu¹, Ai Li¹, Cheng-Bin Chen¹, Wen-Qin Song¹

¹The College of Life Sciences, Nankai University, China
²Basic Medical College, TianJin Medical University, China

**Abstract:** The aim of the study was to explain the mechanism related to therapeutic effects of Uremic Clearance Granules (Niaoduqing Keli in Chinese) on adenine-induced Chronic Renal Failure in rats. Thirty 8-week-old male Wistar rats were selected and randomly divided into 3 groups: Normal Control Group (NCG) consisted of 10 rats, Chronic Renal Failure Pathological Control Group (PCG) 10 rats, and Uremic Clearance Granules Treatment Group (UCG) 10 rats. Each rat in PCG and UCG was fed with adenine-enriched diets, containing 10 g adenine per kg food for 6 weeks. After fed with adenine, each rat in UCG was administered orally with 2 ml solution of Uremic Clearance Granules for 6 weeks. The concentration of Uremic Clearance Granules solution was 0.42 g/ml which was 10 times of human. On days 42 and 84, the serum levels of creatinine, Blood Urea Nitrogen and homocysteine were determined. The methylation of TGF-β₁ promoter was tested by methylation-specific PCR. TGF-β₁ mRNA and protein expression in rat renal cortex were analyzed by real-time RT-PCR and Immunohistochemistry. (1) Experimented on model of Chronic Renal Failure in rats, the preparation was proved to be able to reduce serum creatinine, Blood Urea Nitrogen, and homocysteine (p<0.05), improve renal function. (2) The expression of TGF-β₁ in mRNA and protein level were down-regulated. (3) TGF-β₁ promoter was demethylated at some loci in PCG, and was recovered in UCG. After treatment with Uremic Clearance Granules, the Chronic Renal Failure Wistar rat's kidney function was recovered. The recovery may be result of the remethylation of TGF-β₁ promoter and then lead to TGF-β₁ be transcripted and translated normally. The experimental study explain the molecular mechanism by which Uremic Clearance Granules treat Chronic Renal Failure.

**Key words:** granules, immunohistochemistry, promoter methylation

**Introduction**

The Traditional Chinese Herbal Medicine were useful for some diseases, however, essential compounds have not been identified in most formulae, whereas precise mechanisms of formulae remain to be addressed by using cellular and molecular approaches.

Uremic Clearance Granule (Niaoduqing Keli in Chinese) (Guangzhou Consun Pharmaceutical Co., Ltd, China) was one of traditional Chinese herbal medicine having been used for treatment of Chronic Renal Failure (CRF) in clinic for many years. CRF was characterized by progressive loss of nephrons caused by increased intraglomerular pressure and hyperfiltration. The loss of autoregulatory ability exposes the glomeruli to the systemic blood pressure leading to glomerular hypertrophy and sclerosis. Uremic Clearance Granule attenuated the progression of renal insufficiency in both human and experimental animal models of CRF. In order to address the molecular mechanism of it, we had done some researches using the Wistar rats as the CRF model.

Functions of Uremic Clearance Granule included not only discharging poisonous substances by catharsis, invigorating the spleen and eliminating eczema, but also promoting blood circulation via removing blood stasis. Indication included the patients with azotemia or early stage of ureaemia, which were diagnosed to be hypoplasemia and hygrotoxin syndrome or hypoplasemia and blood stasis syndrome according to the Traditional Chinese Medicine (TCM). The preparation could
decrease both Blood Urea Nitrogen (BUN) and serum Creatinine (sCr), protect the residual renal function, and postpone the beginning of dialysis therapy. It also had some effects on improving the anaemia of renal disease and increasing blood calcium and decreasing blood phosphate.

Hyperhomocysteinaemia (HHcy) occurred in several genetically determined and acquired disorders and was highly prevalent in patients with uraemia [1]. In these disorders, homocysteine precursor S-adenosylhomocysteine (SAH), a powerful competitive inhibitor of S-adenosylmethionine (SAM) -dependent methyltransferases, was increased, suggesting unbalanced methylation. Clinical and experimental studies suggested that HHcy is also a risk factor for CRF [2,3]. The prevalence of HHcy in CRF patients was 82.5%, which was 2 to 3 times of normal level. The accumulation of Hcy in vivo would lead to abnormal methylation of DNA, proteins and other components [4,5].

The most common assay to detect DNA methylation changes was methylation-specific PCR (MSP) [6]. To study the mechanism relates to therapeutic effects of Uremic Clearance Granules, the adenine-induced CRF rats were treated with this TCM. In this study, the serum levels of sCr, BUN and Hcy were determined by Automatic Biochemical Analyzer and High Performance Liquid Chromatography (HPLC). The methylation of TGF-β1 promoter was tested by MSP. TGF-β1 mRNA and protein expression in rat renal cortex were analyzed by real-time RT-PCR and Immunohistochemistry.

Materials and methods

Experimental animals. To get insight into the pharmacological action of Uremic Clearance Granule on CRF, Rat models were developed with CRF-like features induced by adenine-feeding. After 7 days of acclimatization, thirty 8- to 10-week-old male Wistar rats (190 to 210 g; Laboratory Animal Center, The Academy of Military Medical Sciences, China) were randomized into 3 groups: 1 control group (Normal Control Group, NCG) of 10 animals, 1 pathological control group (CRF Pathological Control Group, PCG) of 10 animals, and 1 Uremic Clearance Granule Treatment Group (Uremic Clearance Group, UCG) of 10 animals. The PCG and UCG were fed with adenine-enriched diets containing 10 g adenine (Sigma) per kg food. Except for the added adenine, all diets were of identical composition. After 6-week adenine-feeding, each rat in the UCG was administered orally with 2 ml/d Uremic Clearance Granule solution containing 0.42 g Uremic Clearance Granule (Consun, China) per ml distilled water. The concentration of Uremic Clearance Granules solution was 0.42g/ml which was 10 times of human. The period of TCM treatment lasted 6 weeks. Animals were maintained at a constant humidity (ca. 60%) and temperature (ca. 23°C) with a light/dark cycle of 12 h in our institutional stable with free access to food and water. The study was approved by the Institutional Animal Care and Use Committee of the Tianjin Medical University. We monitored body weight, food consumption, and fluid intake weekly.

We performed capillary blood sampling from the retrobulbar plexus at the end of the 6-week adenine-feeding period and 6-week Uremic Clearance Granule-treating period by use of heparin-coated capillaries. Immediately after blood sampling, serum was separated by centrifugation (10 min at 1500 g) and stored at -80°C until analysis. After the final blood sampling, animals were anesthetized using 10% Chloral Hydrate, and then kidneys were isolated, explanted, and rinsed thoroughly to remove adherent blood. Both kidneys of each rat were isolated, and the renal weights were measured using a Sartorius Genius scale (Sartorius AG). Left kidneys were fixed with 4% formalin and used for immunohistochemical analysis. Right kidneys were divided into 2 aliquots. One aliquot was shock-frozen with liquid nitrogen and stored at -80°C until extraction of RNA. One aliquot was used for the extraction of DNA.

sCr and BUN were detected by Hitachi 7020 Automatic Biochemical Analyzer. Hcy was detected by High Waters-600E Performance Liquid Chromatography.

Measurement of TGF-β1 mRNA expression in renal cortex of CRF rats using real-time RT-PCR with SYBR Green I. Total RNA was extracted by the TRizol® (Promega, USA) according to the manufacturer's instructions. The OD 260 and quality of the RNA were measured using the Nanodrop 1000. Total RNA (2 μg) was reversed transcribed in 20 μl using the Imkrom-Ⅱ Reverse Transcriptase (Promega, USA) and Oligo dT primer according to the manufacturer's instructions.

Two microliters of first strand cDNA samples were subjected to PCR in a volume of 20 μl using 2 μM forward and reverse primer [7] (Table 1) and 0.4 μM primers (each 10 mM dATP, dCTP, dGTP, dTTP, 1× PCR reaction buffer, and 2.5 U Taq DNA polymerase (Takara, Japan). All PCR-assays were conducted in capillaries (20 μl-reaction volume) on an Applied Biosystems 7300 Real-Time PCR System (ABI, USA) using the LC-FastStart DNA Master SYBR Green I kit (Takara, Japan). Conditions were: 95°C for 10 min, 95°C for 45 s, annealing temperatures (Table 1) for 5 s, 72°C for 15 s (40 cycles) and 72°C for 1 min. The melting curve analysis was carried out by monitoring fluorescence signals over the range from 65°C to 95°C in steps of 0.1°C/s. PCP-specific products were determined as a clear single peak at the melting curves above 80°C. The TGF-β1 RNA level was acquired from the value of the threshold cycle (Ct) of the real-time PCR as related to that of GAPDH through

Equation 1: ΔCt=Ct(GAPDH)-Ct(TGF-β1)
Final results expressed at N-fold differences in TGF-β₁ gene expression relative to GAPDH, termed "NTGF-β₁" were determined as

\[ NTGF-β₁ = 2^{ΔCt(TGF-β₁) - ΔCt(GAPDH)} \]

TGF-β₁ promoter methylation status tested by MSP. Genomic DNA (gDNA) was isolated from renal cortex using standard procedures involving the use of proteinase K and phenol extraction. The DNA was checked for quality and quantity by agarose gel electrophoresis and the Nanodrop 1000. Genomic DNA was stored in -20°C.

Bisulfate modification of gDNA has been described previously [6]. In brief, 700 ng (up to 2 µg) DNA was denatured in 50 µl of 0.2 mM NaOH at 37°C for 20 min; 30 µl of freshly prepared 10 mM hydroquinone (Sigma, USA) and 520 µl of 3 M sodium bisulphate (Sigma) at pH 5.0 were added. Incubation was under a layer of mineral oil at 55°C for 14~16 hours. The DNA was purified using the Gene Clean kit (Tiandz, China) and eluted with 100 µl water. Finally, the DNA was desulphonated by a 20 min treatment in 0.3 M NaOH at 37°C, followed by an ethanol precipitation. The DNA pellet was resuspended in 1 mM Tris-HCl, pH 8.0, and stored at -20°C.

MSP was used for the detection of methylation in the promoter regions of the TGF-β₁ gene. Two CpG islands were found in the promoter sequence of TGF-β₁ gene (presented by shadows).

About 100 ng of bisulphate-modified DNA was amplified with primer pairs specific to unmethylated [U primer pairs: d(GTTGATTGTTATTGTTTGTATATGGTTG), d(AAAACCAATTCCACAAACACTC)] or methylated DNA sequences [M primer pairs: d(TAGCGGGGTCGATCGTTATCG), d(AACCGATTCCGCGAACGAC)], respectively. After an initial denaturation at 95°C for 3 min, DNA was amplified in 30 cycles of 95°C for 30 s, 60°C (U primer pair) or 65°C (M primer pair) for 30 s and 72°C for 45 s, followed by a final extension at 72°C for 5 min.

The PCR products were separated by electrophoresis through a 1% agarose gel containing Ethidium Bromide. DNA bands were visualized by ultraviolet light. PCR products were gel purified with an agarose gel DNA fragment recovery kit (Tiandz, China) according to the manufacturer's instructions and were sequenced by Invitrogen (USA).

Data analysis. The data were analyzed using the software SPSS 12.0 for Windows. Data were presented as mean±SD. For comparison between multiple groups, quantitative data were analyzed using one-way ANOVA and additional analysis was carried out using Student’s test for multiple comparisons within treatment groups, or student’s t-test between two groups. P<0.05 was considered significant.

Results

At the beginning of this study, all rats behaved normally. After six weeks, all rats fed with adenine developed a series of reactions. They shows decreased food intake, dishevelled hair, lost weight, and tended to crouch. Meanwhile, they presented diuresis and an increase in water intake. The reaction severity in the rats of PCG was significantly different from those in NCG and UCG, while the rats in NCG behaved normally during the experiment.

sCr, BUN and Hcy decreased in UCG

The sCr and BUN levels were diagnostic indices of renal failure. After 12 weeks of treatment, PCG animals exhibited significant high Cr and BUN concentrations (Table 2). The concentration decreased in the UCG group.

---

**Table 1.** Primer sequences, annealing temperatures, and sizes of generated fragment.

<table>
<thead>
<tr>
<th>Genes</th>
<th>Forward primer (5’→3’)</th>
<th>Reverse primers (5’→3’)</th>
<th>Annealing temperature</th>
<th>Size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAPDH</td>
<td>ACCACAG1CC1AGCCA1AAC</td>
<td>1CCACCC1CTG1TG1GTA</td>
<td>65°C</td>
<td>452bp</td>
</tr>
<tr>
<td>TGF-β₁</td>
<td>TATAAGCA1AATCTG1GCCG</td>
<td>CAGAAC1TG1GCA1GG1TAGCC</td>
<td>62°C</td>
<td>446bp</td>
</tr>
</tbody>
</table>

**Table 2.** Comparison of sCr, BUN and Hcy concentrations in studied groups.

<table>
<thead>
<tr>
<th>Groups</th>
<th>n</th>
<th>sCr (µmol/l)</th>
<th>BUN (mmol/l)</th>
<th>Hcy (µmol/l)</th>
<th>TGF-β₁ mRNA</th>
<th>TGF-β₁ protein (µm²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCG</td>
<td>10</td>
<td>29.3±4.65</td>
<td>7.3±1.27</td>
<td>10.5±1.20</td>
<td>1.190±0.0032</td>
<td>6.1±0.5</td>
</tr>
<tr>
<td>PCG</td>
<td>10</td>
<td>149.6±24.95</td>
<td>33.18±2.95</td>
<td>15.42±1.02</td>
<td>6.448±0.0079</td>
<td>15.9±1.07</td>
</tr>
<tr>
<td>UCG</td>
<td>10</td>
<td>85.00±13.89</td>
<td>19.50±3.20</td>
<td>11.37±1.31</td>
<td>2.672±0.0047</td>
<td>9.9±1.22</td>
</tr>
</tbody>
</table>

* p<0.05 vs. PCG

---

©Polish Histochemical et Cytochemical Society
10.2478/v10042-010-0001-7
After 12 weeks of treatment, PCG animals exhibited significant HHCy (Table 2, Fig. 1). The UCG group developed moderate Hcy concentrations.

**TGF-β1 mRNA and TGF-β1 protein expression decreased in UCG**

Expression levels of TGF-β1 mRNA in renal cortex of NCG, PCG and UCG measured by real-time RT-PCR (Table 2, Fig. 2, 3). Expression of TGF-β1 mRNA at renal cortex in PCG was elevated compared with NCG (p<0.05). However, the expression level in UCG was lower than that in PCG (p<0.05).

Expression of TGF-β1 protein at renal tubules and glomerulus in PCG and UCG was elevated compared with NCG (p<0.05). However, the index in UCG was lower than that in PCG (p<0.05) (Table 2, Fig. 4).
Methylation status of TGF-β1 promoter

Several methods exist to detect changes in the DNA methylation pattern. Most of these techniques use bisulphate treatment to uncover the methylation status. Sodium bisulphate induces methylation-dependent single nucleotide polymorphisms by converting unmethylated cytosine to uracil and, upon PCR amplification, to thymine. 5-methylcytosine is highly resistant to sodium bisulphate treatment and thus becomes amplified as cytosine. Two primers: set one specific for the C-containing sequence, set two binding to T-containing DNA, are used to discriminate between the methylated and unmethylated status of gDNA.

The results were shown as Fig. 5 and 6. To the same DNA sequence, after PCR amplification with methylated primers M and non-methylated primers U, there are 8 specimens showing amplified methylation fragment in NCG, 3 specimens in PCG, and 7 specimens in UCG. On the other hand, there are 2 specimens showing amplified demethylation fragments in NCG, 7 specimens in PCG, and 3 specimens in UCG.

Three PCR products of M primer and 3 PCR products of U primer were sequenced. There were 3 C/T polymorphism in the TGF-β1 gene promoter, loci (-471), (-467) and (-335). The 3 loci were mC in NCG and UCG rats’ TGF-β1 promoter while which were C in PCG rats’ TGF-β1 promoter. In the sequence results, the 3 loci were T in PCG as a result of sodium bisulfate treatment and PCR amplification. The 3 loci were demethylated in PCG and recovered to methylation in UCG.

Discussion

Adenine causes renal disorders in rats. 2,8-dihydropyridine (DHOA), an adenine metabolite, was only slightly soluble in water and crystallizes and/or forms stones in the kidney. Although adenine does not have direct effect on rat kidney, DHOA shows cytotoxicity [8]. Experimented on the model of CRF in Wistar rats, Uremic Clearance Granule, was proved to be able to reduce serum Cr, BUN and Hcy. This result indicated that Uremic Clearance Granule has a protecting effects on kidney function during progression of CRF.

TGF-β1 was named "transforming growth factor" due to its ability to induce normal rat kidney fibroblasts to grow and form colonies in soft agar. TGF-β1 was a powerful multifunctional cytokine that plays roles in cell proliferation, differentiation, migration, immunomodulation and regulation of ECM turnover in the kidney. The dysregulation of TGF-β1 has been linked with the development of nephropathy. It was highly expressed in the kidney and most commonly associated with pathological changes of the kidney. TGF-β1 became the treatment target recently [9-14]. In this study, we have examined the protein and mRNA expression of the TGF-β1 gene in 3 groups by IHC and real-time RT-PCR. A complete loss or low level of TGF-β1 protein and mRNA expression were in NCG. In contrast, a rich level of TGF-β1 protein and mRNA expression were identified in PCG. After the treatment of Uremic Clearance Granule, the level of TGF-β1 protein and mRNA expression decreased in UCG.

DNA methylation in eukaryotes involves addition of a methyl group to the carbon 5 position of the cytosine ring. This reaction was catalyzed by DNA methyltransferase in the context of the sequence 5’-CG-3’, which is
also referred to as a CpG dinucleotide. It is the most common eukaryotic DNA modification and is one of the many epigenetic (alteration in gene expression without a change in nucleotide sequence) phenomena. However, methylation is a reversible modification of DNA participating in epigenetic regulation of gene expression. If we were going to start looking for 'epigenetic signatures' associated with various diseases on the basis of genome-wide chromatin profiling or merely concentrate on specific loci or groups of genes, knowledge of where CpG methylation occurs within the genome (or epigenome) will be invaluable [14]. In addition to advancing basic research, the methylation research has immediate applications for diagnostics, and as epigenetic alterations are potentially reversible, it would have potential applications for therapeutics as well. Genomic DNA methylation profile for human and model organisms would not only provide a reference for subsequent profiling in complex diseases but also promise to enable the characterization of distinct methylation signatures for complex diseases with diagnostic, therapeutic and pharmacodynamics implications. The research on DNA methylation would point to epigenetic marks as potential novel tools for prevention and therapy of complex diseases, such as cardiovascular diseases and renal failure.

DNA methylation helps stabilize chromatin and hypomethylation can lead to genomic instability by predisposing to DNA strand breakage and recombination within dispersed repetitive sequences. Furthermore, promoter CpG hypomethylation can result in gene activation, also contributing to aberrant gene expression [15]. For example, increased heparanase expression during the development of bladder cancer is due to promoter CpG hypomethylation of early growth response gene-1 (EGR1) [16]. An earlier study from our laboratory demonstrated a global hypomethylation pattern of genomic DNA in CRF rat's renal cortex [17]. Previous study has shown that demethylation of the TGF-β1 promoter was in human lung and prostate cancer [18]. 509C→T polymorphism in the TGF-β1 promoter impact on the hepatocellular carcinoma risk in Chinese patients with chronic hepatitis B virus infection [19]. In this study, we have examined the promoter methylation status of the TGF-β1 gene in 3 groups using an optimized MSP method. A complete loss or low level of TGF-β1 mRNA expression was in NCG. In contrast, only sparsely methylated or unmethylated CpG sites were identified in PCG with a rich level of TGF-β1 mRNA. Our study revealed that change of TGF-β1 promoter methylation was correlated with the development of CRF, and with the treatment of Uremic Clearance Granule. Increased TGF-β1 expression during the development of CRF was a critical step in rat and human glomerulosclerosis. TGF-β1 promoter CpG hypomethylation may be one of the mechanisms causing TGF-β1 overexpression in glomerulosclerosis.

In CRF, high plasma homocysteine levels are a common finding and in uremia almost the rule. Ingrosso D's study suggested that hyperhomocysteinaemia affects epigenetic control of gene expression and the toxic action of homocysteine can be mediated by macromolecule hypomethylation. Hypomethylation is a major mechanism of adverse Hcy effects [20,21]. Hyperhomocysteinaemia and unbalanced methylation were also found in uremia patients [1]. Our results showed that an increased Hcy concentration and downgrading of the DNA methylation level [17]. Aberrant DNA methylation status of individual genes was a hallmark of cancer and had been shown to play an important role in neurological disorders such as Rett syndrome. We extrapolated that the renal genomic DNA demethylation promoted some cytokines, such as TGF-β1 gene expression, caused proliferation of mesangial cell and ECM, and then participated progression of glomerulosclerosis. Uremic Clearance Granule treatment could restored DNA methylation to normal levels and corrected the patterns of gene expression. Clearance of Hcy has led to recovery of some genes methylation statue may be one of molecular mechanisms of Uremic Clearance Granules as an effective treatment for CRF.

Compositions of Uremic Clearance Granule included Radix et Rhizoma Rhei, Radix Astragali, Raeix Glycyrrhizae, Poria, Rhizoma Atractylodis Macrocephalae, Radix Polygoni Multiflori, Rhizoma Chuanxiong, Flos Chrysanthemi, Radix Salviae Miltiorrhizae, and Rhizoma Pinelliae.

Radix Astragali was the principal component of Uremic Clearance Granule. Previous clinical and experimental studies have confirmed that Radix Astragali and the formula with Radix Astragali as the principal com-

**Fig. 6.** DNA sequencing results. (A): DNA sequencing result of demethylation fragment in PCG; (B): DNA sequencing result of methylation fragment in UCG.
ponent had a wide range of effectiveness on CRF treatment, such as reduce proteinuria, inhibit mesangial cell proliferation, reduce IL-6 secretion and regulate immune function [22-26]. This study showed that Uremic Clearance Granule which takes Radix Astragali as the principal component could reduce not only TGF-β1 mRNA expression but TGF-β1 protein expression. The inhibition effect on glomerulosclerosis of Radix Astragali may be one of the mechanisms of Uremic Clearance Granule as an effective treatment of CRF and delaying chronic progressive renal function deterioration. The study, in cellular and molecular level, provides some theoretical basis for Uremic Clearance Granule to prevent of glomerulosclerosis in clinical application.

Emodin (EMD) was the most widespread type of single-anthraquinone nuclear 1, 8-dihydroxyanthraquinone derivatives in anthracene derivatives. EMD was the main active ingredient of Radix et Rhizoma Rhei and Rhizoma Atractylodis Macrocephalae [27]. Studies showed that in recent years, EMD had a variety of pharmacological effects, including tumor suppression, anti-virus, anti-oxidation and immune suppression, etc. Studies also found that, in patients with CRF, EMD could not only inhibit serum tumor necrosis factor secretion and mesangial cell proliferation, but also reduce IL-6 secretion of mesangial cells and the ECM accumulation [28,29]. In the human embryonic kidney fibroblasts (KFB), EMD could reduce PAI-1 secretion and increase ECM degradation [30]. In accordance with the results of this study, we would speculate that TGF-β1 mRNA expression decrease was likely associated with the role of EMD.

Studies have shown that Radix Astragali could inhibit the proliferation of vascular smooth muscle cells [31]. In our experiment, it was also found that the heart size of rats in UCG was smaller than which in PCG. We would speculate the result may be associated with the inhibition of Radix Astragali on vascular smooth muscle cells proliferation. Min Liang [32] suggests that homocysteine can stimulate the proliferation of myocardial cells involved in CRF patients with the occurrence of cardiac hypertrophy. In this study, rats in PCG suffered from serious cardiac hypertrophy, while rats in UCG did slightly.

In conclusion, the present results indicate that the CRF Wistar rat's kidney function was recovered after treatment with Uremic Clearance Granules. The recovery may be result of the remethylation of TGF-β1 promoter and then lead to TGF-β1 be transcribed normally. Clearance of Hcy may be the important mechanism of Uremic Clearance Granules. Lan Wang [33] suggested that dissecting the mode of action of clinically effective formulae at the molecular, cellular, and organism levels may be a good strategy in exploring the value of Chinese Traditional Medicine. Study on epigenetic changes in process of CRF and TCM treatment could provide a new theoretical foundation for the prevention and treatment to CRF. With the development of biotechnology, improvement of diagnosis and treatment of CRF at the molecular level may be the direction of TCM research and development.

Acknowledgements: The author acknowledge Doctor Bin Yang in the Third Central Hospital of TianJin for primers design, Professor Tong-Shun Zhang in the Second Affiliated Hospital of TianJin Medical University for HPLC test, Technician Yong-Ming Wang in Toxicological Department of TianJin Medical University for CRF rat model development. The study was supported by the Tianjin Natural Science and Technology Program (06YFJMC10000) and the Tianjin Key Science and Technology Program (07ZCGYSF00700).

References


Submitted: 29 October, 2009
Accepted after reviews: 10 February, 2010